The DARVIN trial, a multicenter, nonrandomized phase 2 study led by investigators including H. Mo, Y. Teng and L. Cai, evaluated dalpiciclib — a selective CDK4/6 inhibitor — in combination with endocrine therapy in women with HR-positive/HER2-negative advanced breast cancer experiencing visceral crisis. The results were striking: of 53 participants enrolled, 49 survived beyond six months, translating into a six-month survival rate of 92.5 percent, with a 95 percent confidence interval ranging from 81.8 to 97.9 percent. The study met its primary endpoint, and the finding represents one of the strongest signals yet that CDK4/6 blockade can meaningfully change outcomes in this notoriously fragile patient population.

To understand why this matters, it helps to appreciate the biology. HR-positive breast cancers remain dependent on the estrogen receptor signaling axis, which drives cell-cycle progression. CDK4/6 inhibitors such as dalpiciclib work downstream of the estrogen receptor, blocking the cyclin D–CDK4/6 complex that phosphorylates the retinoblastoma protein and thereby releases the cell into the DNA synthesis phase of the cell cycle. By halting this phosphorylation step, the drug enforces a G1 arrest, effectively putting tumor cells into a state of senescence-like quiescence. Combined with endocrine therapy — which suppresses estrogen signaling at the receptor level — the two agents attack the same proliferative machinery at complementary points. In ordinary HR-positive metastatic disease, this combination is already standard of care. The visceral crisis setting is different: the disease is behaving aggressively, organs are failing under tumor burden, and clinicians have historically doubted whether a slow-acting hormonal approach could keep pace.

The trial’s design reflected that skepticism. Rather than measuring tumor shrinkage alone, the investigators chose six-month survival as the primary endpoint — a hard, clinically meaningful measure of whether patients could actually live long enough to benefit from treatment. Secondary endpoints included overall survival, progression-free survival, time to treatment failure, the three-month treatment failure rate, duration of disease control, objective response rate, disease control rate and safety. This endpoint architecture is deliberately patient-centered: in visceral crisis, where median survival in historical cohorts can be measured in a few months, simply keeping the majority of patients alive at half a year is a consequential goal.

The secondary outcomes painted a consistent picture of durable benefit. The objective response rate — the proportion of patients whose tumors shrank measurably — was 26.4 percent, while the disease control rate, which includes both shrinkage and stable disease, reached 79.2 percent. Only 22.6 percent of patients experienced treatment failure within the first three months, indicating that the vast majority of patients obtained at least short-term control of their disease during the most dangerous window. The median progression-free survival was 11.2 months (95 percent CI: 7.6–19.3), a duration that exceeds what many observers would have predicted for a population this ill. Duration of disease control reached 14.1 months (95 percent CI: 8.4–21.5), and time to treatment failure was 10.2 months (95 percent CI: 6.4–15.6). Notably, the median overall survival had not been reached at the time of analysis — meaning that more than half of the enrolled patients were still alive when the data were cut, a remarkable fact for a cohort defined by visceral crisis.

Safety data were consistent with the known profile of CDK4/6 inhibitors. The most common grade 3 or higher adverse events were hematologic: decreased neutrophil counts occurred in 77.4 percent of patients and decreased white blood cell counts in 54.7 percent. These effects reflect the drug’s mechanism of action on normal bone marrow cells, which also use the CDK4/6 pathway for proliferation. Importantly, neutropenia caused by CDK4/6 inhibition is typically reversible and rarely complicated by infection in the way chemotherapy-induced neutropenia can be, because the drug preserves lymphocyte populations relatively well. The data suggest that, with appropriate monitoring and dose modification, the regimen was manageable even in a high-acuity population.

Perhaps the most intriguing finding of the study, however, lies beyond the survival curves. In exploratory analyses, the investigators examined cell-free DNA — fragments of tumor and host DNA circulating in the blood — and stratified patients by the contribution of monocyte-derived cfDNA at baseline. Patients whose baseline monocyte-derived cfDNA level was below a threshold of 0.0581 had significantly worse overall survival, with a hazard ratio of 4.79 (95 percent CI: 1.05–45.47, P = 0.0394). The authors interpret this as evidence of a “molecular crisis” — a systemic inflammatory and immune state detectable in the bloodstream that predicts poor outcomes even among patients receiving an effective regimen. The concept is compelling: it suggests that visceral crisis is not merely a matter of tumor burden in organs, but of a broader biological state in which host immune and inflammatory dynamics, measurable through liquid biopsy, define prognosis.

The implications of this biomarker finding are twofold. Clinically, if validated, monocyte-derived cfDNA could help identify which patients with apparent visceral crisis might need escalation beyond endocrine-based therapy — for example, to chemotherapy — and which could safely remain on a CDK4/6 inhibitor combination. Scientifically, it reframes visceral crisis as a measurable molecular phenotype rather than a purely radiographic or symptomatic category. Circulating DNA carrying monocyte-associated signatures may reflect an immune system in distress, or a tumor microenvironment that has shifted toward a pro-inflammatory, treatment-resistant state. Disentangling that biology could open new therapeutic avenues beyond cell-cycle inhibition.

The DARVIN results arrive amid growing attention to how CDK4/6 inhibitors are deployed in the sequencing of metastatic breast cancer treatment. Dalpiciclib, developed in China and approved there for HR-positive/HER2-negative advanced breast cancer, joins abemaciclib, palbociclib and ribociclib in a class that has transformed outcomes across the disease continuum. Most prior evidence in visceral crisis has come from subgroup analyses of larger trials or from retrospective series, and those data have been inconsistent. A dedicated prospective trial — even a single-arm, nonrandomized one — specifically designed around visceral crisis patients is unusual, and the 92.5 percent six-month survival figure provides a benchmark against which future studies and combination strategies can be measured.

Caveats remain. The trial was nonrandomized and enrolled 53 patients, so the results cannot exclude selection effects, and there is no internal control arm against which to compare the survival benefit. Median overall survival was not reached, meaning longer follow-up will be needed to characterize the ultimate duration of benefit. The cfDNA threshold finding is exploratory and described with wide confidence intervals, and it will require independent validation before influencing practice. Nevertheless, the study is registered (ClinicalTrials.gov: NCT05431504) and the investigators argue that the data support further evaluation of dalpiciclib plus endocrine therapy in this population, ideally in randomized settings that could also test biomarker-guided strategies.

For patients and clinicians facing visceral crisis today, the study adds weight to a shifting consensus: that aggressive HR-positive disease in organs is not automatically synonymous with chemotherapy, and that rapidly acting endocrine-CDK4/6 combinations — under close monitoring — can achieve both tumor control and survival. As the field moves toward integrating liquid biopsy readouts such as monocyte-derived cfDNA into routine decision-making, the DARVIN trial stands as an early signal that molecular profiling may eventually distinguish which patients in crisis will thrive on targeted therapy and which truly need something more. The broader lesson is that “visceral crisis,” long treated as a monolithic red flag in breast cancer oncology, is being dismantled into biological substates — some of which, it turns out, are far more treatable than their reputation suggests.

The study, published in Genome Medicine, examined acquired resistance to CDK4/6 inhibitors, drugs that have transformed the treatment of advanced estrogen receptor-positive breast cancer. These medicines are commonly given with endocrine therapy, which blocks estrogen signaling or interferes with the estrogen receptor. CDK4/6 inhibitors attack a different part of the growth machinery: they restrain cyclin-dependent kinases 4 and 6, proteins that help push cells from a resting phase into DNA replication. By interrupting this cell-cycle transition, the drugs can slow or stop tumor expansion. Yet most metastatic tumors eventually resume growing. Activating ESR1 mutations are already recognized as a frequent route to resistance against endocrine therapy, but their independent contribution to resistance against CDK4/6 inhibition has been far less clear.

To isolate that contribution, the researchers built an isogenic model using MCF7 breast-cancer cells. The cells were genetically matched except for the form of estrogen receptor they carried: one group expressed the normal, or wild-type, receptor, while another expressed the Y537S mutant form of ER, a common activating ESR1 mutation. This design allowed the investigators to compare resistance evolution while holding much of the cellular background constant. They then exposed the cells to either palbociclib or abemaciclib, two CDK4/6 inhibitors, and followed the populations over time. The team combined high-complexity DNA barcoding with molecular profiling, effectively giving thousands of cancer-cell lineages unique genetic “names” that could be tracked as treatment removed some populations and allowed others to expand.

This lineage-tracing strategy captured a feature that conventional drug-sensitivity tests can miss. A tumor may appear to be a single mass, but it is typically a crowded ecosystem containing many related subclones. Some may already carry mutations that confer a survival advantage, while others may not be genetically resistant but can temporarily alter their behavior when exposed to stress. As treatment continues, the drug changes the population’s environment. Sensitive clones shrink or disappear, resistant clones expand and previously minor populations can become dominant. The researchers observed progressive clonal selection under both inhibitors, with some evolutionary paths diverging and others partially converging on similar resistant states. In other words, different starting populations could reach overlapping biological solutions, even though the precise clones and regulatory changes involved were not identical.

The effect of the estrogen-receptor mutation was especially pronounced during selection with palbociclib. In cells carrying ER-Y537S, the mutation substantially reshaped both clonal evolution and epigenetic evolution—the changes in chromatin accessibility and gene regulation that influence which genes a cell can use without altering the DNA sequence itself. The same mutation had a weaker effect under abemaciclib selection. This difference is important because palbociclib and abemaciclib inhibit the same broad protein targets but are not biologically interchangeable. They differ in potency, selectivity, dosing behavior and effects on cell-cycle control, and abemaciclib can inhibit additional kinases at clinically relevant concentrations. The results indicate that each drug creates its own selective landscape, favoring distinct combinations of pre-existing traits and treatment-induced adaptations.

The study also showed that resistance is not explained by genetics alone. Single-cell RNA sequencing revealed pronounced transcriptional heterogeneity as cells were passaged and exposed to drug selection. Individual cells within the same resistant population could occupy different functional states, including states associated with altered proliferation, stress responses, lineage programs and cellular plasticity. Plasticity refers to a cell’s ability to shift its phenotype in response to changing conditions. A cell that temporarily enters a slow-cycling or altered regulatory state may survive therapy without immediately acquiring a new resistance mutation. If treatment persists, that state can provide time for more stable genetic or epigenetic changes to emerge. This layered process helps explain why resistance can develop gradually and why a resistant tumor may remain vulnerable to a different therapeutic pressure.

The researchers extended their analysis beyond cultured cells by studying patient tumor samples. They found that ESR1 mutations were enriched in clinical tumors that had acquired resistance to CDK4/6 inhibitors. In paired biopsies taken before and after treatment, mutant cancer-cell populations expanded until they approached clonality, meaning that the mutation was present in nearly all of the sampled tumor cells. Such expansion is a strong sign of treatment-driven selection: the mutation may have been present in only a minority of cells initially, but therapy created conditions in which those cells gained a decisive advantage. The finding does not mean that every resistant tumor is dominated by an ESR1 mutation, nor that the mutation alone explains resistance. Instead, it places the receptor mutation within a broader evolutionary process involving competing clones, adaptable cell states and drug-specific pressures.

Experiments in mice added another layer to the picture by tracing barcoded cancer cells in mammary tumors, local recurrences and distant metastases. The investigators observed site-specific clonal outgrowth in tumors carrying mutant estrogen receptors. Different anatomical sites favored different subclones, suggesting that the tissue environment can act as another filter during cancer evolution. Some subpopulations overlapped between metastatic lesions and CDK4/6-inhibitor-resistant tumors, supporting the possibility that particular cancer-cell groups can perform a dual role: surviving treatment in one setting while also possessing traits that help them colonize distant organs. However, the overlap was only partial. Resistance and metastatic spread therefore appear related but not identical, with each process selecting for some shared and some distinct characteristics.

The implications extend to how oncologists think about treatment after CDK4/6 inhibitor failure. The results argue against viewing resistance as a uniform condition that can be treated with one universal sequence of drugs. Instead, the most effective next therapy may depend on whether a tumor carries an activating ESR1 mutation, which CDK4/6 inhibitor was used first and which cellular states emerged during treatment. Molecular tests that identify receptor mutations are already relevant to endocrine-treatment decisions, but the new work suggests they could also help interpret the evolutionary history of CDK4/6 inhibitor resistance. Future strategies might combine drugs that target estrogen-receptor signaling with agents aimed at cell-cycle control or the adaptive states that allow cancer cells to persist. Such approaches will require clinical testing, because findings from engineered cell models and mouse xenografts cannot by themselves predict patient benefit.

The central message is that cancer resistance is a moving target rather than a fixed lock that one key fails to open. By combining lineage tracing, DNA sequencing, chromatin analysis and single-cell transcriptomics, the researchers were able to watch resistant populations emerge at several biological scales—from individual clones to shifting gene-expression states and tumor growth in different organs. Their findings show that ESR1 mutation status and inhibitor choice jointly shape the route a tumor takes under treatment. Mapping those routes could make resistance more predictable and could encourage treatment plans designed not merely to kill the dominant cancer population, but also to prevent minor, adaptable clones from becoming the next dominant threat.

Subject of Research: Clonal evolution and adaptive cell states underlying CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer

Article Title: ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance

Article References: Guarducci, C., Abravanel, D., Russo, D. et al. “ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.” Genome Medicine (2026). Original research article

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01690-2

Keywords: estrogen receptor-positive breast cancer, ESR1 mutations, CDK4/6 inhibitor resistance, palbociclib, abemaciclib, clonal evolution, cancer cell plasticity, metastatic colonization